Recent Analyst Upgrade: Recent discussions on social media have highlighted a significant upgrade for Recursion Pharmaceuticals by a major financial institution, with some expressing optimism about a potential multi-fold increase in stock price. Many users are intrigued by the company’s use of AI in drug discovery, viewing it as a unique growth driver. The buzz suggests a growing interest in the stock’s future potential.
Insider Trading Concerns: There’s also chatter about recent insider sales at the company, with some social media users questioning the timing and implications of these transactions. This has sparked debate about the confidence of company executives in the near-term outlook. Despite this, others remain focused on long-term prospects tied to AI-driven innovation.
Institutional Investment Boost: Lastly, news of substantial share purchases by institutional investors has fueled positive conversations on social media platforms. Some see this as a vote of confidence in Recursion’s strategy, while others caution about the inherent risks in the biotech sector. The mix of opinions keeps the discussion lively and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 12 sales selling 1,278,175 shares for an estimated $6,608,964.
- BLAKE BORGESON sold 220,000 shares for an estimated $961,400
- NAJAT KHAN (Chief R&D Commercial Officer) has made 0 purchases and 2 sales selling 161,002 shares for an estimated $750,765.
- BEN R TAYLOR (Chief Financial Officer) sold 21,383 shares for an estimated $89,380
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenues of $5.2M in Q3 2025. This is a decrease of -80.16% from the same period in the prior year.
You can track RXRX financials on Quiver Quantitative's RXRX stock page.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 176 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 7,089,386 shares (+63.4%) to their portfolio in Q3 2025, for an estimated $34,596,203
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,778,440 shares (+81.9%) to their portfolio in Q3 2025, for an estimated $18,438,787
- VANGUARD GROUP INC added 3,708,975 shares (+10.3%) to their portfolio in Q3 2025, for an estimated $18,099,798
- BLACKROCK, INC. added 3,368,702 shares (+11.9%) to their portfolio in Q3 2025, for an estimated $16,439,265
- FMR LLC removed 2,356,001 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $11,497,284
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 2,183,837 shares (+68.1%) to their portfolio in Q3 2025, for an estimated $10,657,124
- GEODE CAPITAL MANAGEMENT, LLC added 1,847,149 shares (+23.8%) to their portfolio in Q3 2025, for an estimated $9,014,087
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/17/2025
- Needham issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 2 analysts offer price targets for $RXRX in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Eric Joseph from JP Morgan set a target price of $11.0 on 12/17/2025
- Gil Blum from Needham set a target price of $8.0 on 09/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
